Evi Lemmens

Evi Lemmens

Auto-generated profile, based on publicly available information

Evi Lemmens

Department of Morphology, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
PVPía M. Vidal
Pía M. Vidal
ELEvi Lemmens
Evi Lemmens
Dearbhaile DooleyDearbhaile Dooley
Dearbhaile Dooley
SHSven Hendrix
Sven Hendrix

13 February 2013 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
SNSofie Nelissen
Sofie Nelissen
ELEvi Lemmens
Evi Lemmens
NGNathalie Geurts
Nathalie Geurts
PKPeter Kramer
Peter Kramer
MMMarcus Maurer
Marcus Maurer
SHSven Hendrix
Sven Hendrix

1 December 2016 in Stem Cell Reports
Verified
Journal Article
Open access
Dearbhaile DooleyDearbhaile Dooley
Dearbhaile Dooley
ELEvi Lemmens
Evi Lemmens
TVTim Vangansewinkel
Tim Vangansewinkel
DBDebbie Le Blon
Debbie Le Blon
CHChloé Hoornaert
Chloé Hoornaert
SHSven Hendrix
Sven Hendrix
The therapeutic effects of mesenchymal stem cell (MSC) transplantation following spinal cord injury (SCI) to date have been limited. Therefore, we aimed to enhance the immunomodulatory properties of MSCs via continuous secretion of the anti-inflammatory cytokine interleukin-13 (IL-13). By using MSCs as carriers of IL-13 (MSC/IL-13), we investigated their therapeutic potential, compared with non-engineered MSCs, in a mouse model of SCI. We show that transplanted MSC/IL-13 significantly improve functional recovery following SCI, and also decrease lesion size and demyelinated area by more than 40%. Further histological analyses in CX3CR1EGFP/+ CCR2RFP/+ transgenic mice indicated that MSC/IL-13 significantly decrease the number of resident microglia and increase the number of alternatively activated macrophages. In addition, the number of macrophage-axon contacts in MSC/IL-13-treated mice was decreased by 50%, suggesting a reduction in axonal dieback. Our data provide evidence that transplantation of MSC/IL-13 leads to improved functional and histopathological recovery in a mouse model of SCI.

1 June 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JPJose Guzman Parra
Jose Guzman Parra
PBPilar Barnestein-Fonseca
Pilar Barnestein-Fonseca
GGGloria Guerrero-Pertiñez
Gloria Guerrero-Pertiñez
Peter AnderbergPeter Anderberg
Peter Anderberg
LJLuis Jimenez-Fernandez
Luis Jimenez-Fernandez
FMFermin Mayoral
Fermin Mayoral
Background: Information and communication technologies are promising tools to increase the quality of life of people with dementia or mild cognitive impairment and that of their caregivers. However, there are barriers to their use associated with sociodemographic factors and negative attitudes, as well as inadequate knowledge about technologies. Objective: The aim of this study was to analyze technophilia (attitudes toward new technologies) and the use of smartphones and tablets along with associated factors in people with dementia/mild cognitive impairment and their caregivers. Methods: Data from the first visit of the Support Monitoring and Reminder for Mild Dementia (SMART4MD) randomized multicenter clinical trial were used for this analysis. Data were obtained from two European countries, Spain and Sweden, and from three centers: Consorci Sanitari de Terrassa (Catalonia, Spain), Servicio Andaluz de Salud (Andalusia, Spain), and the Blekinge Institute of Technology (Sweden). Participants with a score between 20 and 28 in the Mini Mental State Examination, with memory problems (for more than 6 months), and who were over the age of 55 years were included in the study, along with their caregivers. The bivariate Chi square and Mann-Whitney tests, and multivariate linear and logistic regression models were used for statistical analysis. Results: A total of 1086 dyads were included (N=2172). Overall, 299 (27.53%) of people with dementia/mild cognitive impairment had a diagnosis of dementia. In addition, 588 (54.14%) of people with dementia/mild cognitive impairment reported using a smartphone almost every day, and 106 (9.76%) used specific apps or software to support their memory. Among the caregivers, 839 (77.26%) used smartphones and tablets almost every day, and 181 (16.67%) used specific apps or software to support their memory. The people with dementia/mild cognitive impairment showed a lower level of technophilia in comparison to that of their caregivers after adjusting for confounders (B=0.074, P=.02) with differences in technology enthusiasm (B=0.360, P<.001), but not in technology anxiety (B=–0.042, P=.37). Technophilia was associated with lower age (B=–0.009, P=.004), male gender (B=–0.160, P<.001), higher education level (P=.01), living arrangement (living with children vs single; B=–2.538, P=.01), country of residence (Sweden vs Spain; B=0.256, P<.001), lower depression (B=–0.046, P<.001), and better health status (B=0.004, P<.001) in people with dementia/mild cognitive impairment. Among caregivers, technophilia was associated with comparable sociodemographic factors (except for living arrangement), along with a lower caregiver burden (B=–0.005, P=.04) and better quality of life (B=0.348, P<.001). Conclusions: Technophilia was associated with a better quality of life and sociodemographic variables in people with dementia/mild cognitive impairment and caregivers, suggesting potential barriers for technological interventions. People with dementia/mild cognitive impairment frequently use smartphones and tablets, but the use of specific apps or software to support memory is limited. Interventions using these technologies are needed to overcome barriers in this population related to sociodemographic characteristics and the lack of enthusiasm for new technologies. Trial Registration: ClinicalTrials.gov NCT03325699; https://clinicaltrials.gov/ct2/show/NCT03325699

28 September 2005 in Epilepsia
Verified
Journal Article
Closed access
ELEvi M. P. Lemmens
Evi M. P. Lemmens
TLTim Lubbers
Tim Lubbers
OSOlaf E. M. G. Schijns
Olaf E. M. G. Schijns
EBEmile A. M. Beuls
Emile A. M. Beuls
GHGovert Hoogland
Govert Hoogland

27 November 2012 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SHSven Hendrix
Sven Hendrix
PKPeter Kramer
Peter Kramer
DPDebora Pehl
Debora Pehl
KWKatharina Warnke
Katharina Warnke
FBFrancesco Boato
Francesco Boato
MMMarcus Maurer
Marcus Maurer
Mast cells (MCs) are found abundantly in the brain and the meninges and play a complex role in neuroinflammatory diseases, such as stroke and multiple sclerosis. Here, we show that MC‐deficient Kit W /Kit Wv mice display increased neurodegeneration in the lesion area after brain trauma. Furthermore, MC‐deficient mice display significantly more brain inflammation, namely an increased presence of macrophages/microglia, as well as dramatically increased T‐cell infiltration at days 4 and 14 after injury, combined with increased astrogliosis at day 14 following injury. The number of proliferating Ki67 + macrophages/microglia and astrocytes around the lesion area is more than doubled in these MC‐deficient mice. In parallel, MC‐deficient Kit W‐sh / W‐sh mice display increased presence of macrophages/microglia at day 4, and persistent astrogliosis at day 4 and 14 after brain trauma. Further analysis of mice deficient in one of the most relevant MC proteases, i.e. , mouse mast cell protease 4 (mMCP‐4), revealed that astrogliosis and T‐cell infiltration are significantly increased in mMCP‐4‐knockout mice. Finally, treatment with an inhibitor of mMCP‐4 significantly increased macrophage/microglia numbers and astrogliosis. These data suggest that MCs exert protective functions after trauma, at least in part via mMCP‐4, by suppressing exacerbated inflammation via their proteases.—Hendrix, S., Kramer, P., Pehl, D., Warnke, K., Boato, F., Nelissen, S., Lemmens, E., Pejler, G., Metz, M., Siebenhaar, F., Maurer, M. Mast cells protect from post‐traumatic brain inflammation by the mast cell‐specific chymase mouse mast cell protease‐4 . FASEB J. 27, 920–929 (2013). www.fasebj.org